Several studies have reported and concluded that inhibition of COX may decrease the risk for colorectal cancer (CRC) and subsequent death[1-5], while other studies have indicated favorable anti-EGFR treatment of CRC; a treatment which is already in clinical use[6,7]. This evidence concerns the gene EGFR and colorectal cancer.